Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens
Open Access
- 1 January 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 18, 2247-2258
Abstract
The status quo for combating uprising antibacterial resistance is to employ synergistic combinations of antibiotics. Nevertheless, the currently available combination therapies are fast becoming untenable. Combining antibiotics with various FDA-approved non-antibiotic drugs has emerged as a novel strategy against otherwise untreatable multi-drug resistant (MDR) pathogens. The apex of this study was to investigate the mechanisms of antibacterial synergy of the combination of polymyxin B with the phenothiazines against the MDR Gram-negative pathogens Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa. The synergistic antibacterial effects were tested using checkerboard and static time-kill assays. Electron microscopy (EM) and untargeted metabolomics were used to ascertain the mechanism(s) of the antibacterial synergy. The combination of polymyxin B and the phenothiazines showed synergistic antibacterial activity in checkerboard and static time-kill assays at clinically relevant concentrations against both polymyxin-susceptible and polymyxin-resistant isolates. EM revealed that the polymyxin B-prochlorperazine combination resulted in greater damage to the bacterial cell compared to each drug monotherapy. In metabolomics, at 0.5 h, polymyxin B monotherapy and the combination (to a greatest extent) disorganised the bacterial cell envelope as manifested by a major perturbation in bacterial membrane lipids (glycerophospholipids and fatty acids), peptidoglycan and lipopolysaccharide (LPS) biosynthesis. At the late time exposure (4 h), the aforementioned effects (except LPS biosynthesis) perpetuated mainly with the combination therapy, indicating the disorganising bacterial membrane biogenesis is potentially behind the mechanisms of antibacterial synergy. In conclusion, the study highlights the potential usefulness of the combination of polymyxin B with phenothiazines for the treatment of polymyxin-resistant Gram-negative infections (e.g. CNS infections).Keywords
Funding Information
- National Health and Medical Research Council
This publication has 43 references indexed in Scilit:
- The pmrCAB Operon Mediates Polymyxin Resistance in Acinetobacter baumannii ATCC 17978 and Clinical Isolates through Phosphoethanolamine Modification of Lipid AAntimicrobial Agents and Chemotherapy, 2011
- Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory SystemAntimicrobial Agents and Chemotherapy, 2011
- Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide ProductionAntimicrobial Agents and Chemotherapy, 2010
- Structure−Activity Relationships of Polymyxin AntibioticsJournal of Medicinal Chemistry, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- The in-vitro antimicrobial effect of non-antibiotics and putative inhibitors of efflux pumps on Pseudomonas aeruginosa and Staphylococcus aureusInternational Journal of Antimicrobial Agents, 2003
- Antifungal Activity of Nonantifungal DrugsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- The Pharmacokinetics and Effects of Prochlorperazine in Elderly Female VolunteersAge and Ageing, 1992
- THE ANTIBACTERIAL EFFECT OF SELECTED PHENOTHIAZINES AND THIOXANTHENES ON SLOW‐GROWING MYCOBACTERIAActa Pathologica Microbiologica Scandinavica Series B: Microbiology, 1986
- The chemistry of the polymyxin antibioticsCellular and Molecular Life Sciences, 1966